Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Snap Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Snap Inc trades at $6.05 (market cap $10.98B). The key difference: Snap Inc is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Snap Inc for 68 Days on average.
| KYMR | SNAP | |
|---|---|---|
Market Cap | $8.87B | $10.98B |
Volume | 779,107 | 53,140,165 |
Sector | Health | Media |
52-Week High | $127.31 | $9.09 |
52-Week Low | $55.80 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $8.26B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snap Inc. (SNAP) trades at $6.10, down 6.73% over 24 hours, with technical indicators showing a bullish trend despite overbought RSI signals. The company reported revenue growth to $5.93B in 2025, though net losses persist at -$460M, with improving margins. Recent news highlights AI and AR developments, including SPECS glasses partnerships with NVIDIA and Salesforce, driving investor optimism amid regulatory pressures.
The outlook remains cautious; while analyst consensus is a $7.91 price target with 38% buy ratings, risks include sustained losses, high debt, and competitive threats. Upside hinges on monetizing AI innovations and achieving profitability, but volatility from sentiment shifts poses near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
